Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HER2 gene (ERBB2) amplification is a rare event in non-liver-fluke associated cholangiocarcinogenesis

1 Dec 2019

Abstract excerpt

BACKGROUND: Cholangiocarcinoma is a rapidly fatal cancer entity with a median survival of less than one year. In contrast to many other malignancies, no substantial therapeutic breakthrough has been made in the past few decades, thereby limiting the treatment to cytotoxic chemotherapy with little beneficial effect for most patients. Targeted therapy tailored to the individual has shown substantial success in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cholangiocarcinoma and Gallbladder Cancer Studies
Share to Gallbladder and Bile Duct Disorders
Share to HER2/EGFR in Cancer Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31805897
DOI: 10.1186/s12885-019-6320-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HER2 gene (ERBB2) amplification is a rare event in non-liver-fluke associated cholangiocarcinogenesisPMID 31805897Read ↗

ERBB2 Pathway in Biliary Tract Carcinoma: Clinical Implications of a Targetable Pathway.Semantic proximity Read ↗

Characterization of EGFR family gene aberrations in cholangiocarcinomaSemantic proximity Read ↗

HER2 amplification subtype intrahepatic cholangiocarcinoma exhibits high mutation burden and T cell exhaustion microenvironment.Semantic proximity Read ↗

Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer.Semantic proximity Read ↗

Molecular Testing for Intrahepatic Cholangiocarcinoma: What, When, How?Semantic proximity Read ↗

Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testingSemantic proximity Read ↗

Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets.Semantic proximity Read ↗

Targeting ERBB2/HER2 genetic alterations: an expanding therapeutic opportunity in gastrointestinal cancers.Semantic proximity Read ↗

Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinomaSemantic proximity Read ↗

HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists.Semantic proximity Read ↗

Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study.Semantic proximity Read ↗

FGFR2 Inhibition in Cholangiocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.